The Emerging Role of Off-the-shelf Engineered Natural Killer Cells in Targeted Cancer Immunotherapy

Overview

Journal Mol Ther Oncolytics

Publisher Cell Press

Date 2021 Nov 11

PMID 34761106

Citations 31

Authors

Kellsye P Fabian

James W Hodge

Affiliations

Soon will be listed here.

Abstract

Natural killer (NK) cells are innate lymphocytes that recognize and clear infected and transformed cells. The importance of NK cells in tumor surveillance underlies the development of NK cell therapy as cancer treatment. The NK-92 cell line has been successfully modified to express high-affinity CD16 receptor for antibody-dependent cellular cytotoxicity and/or chimeric antigen receptors (CARs) that can recognize antigens expressed on tumor cells and mediate NK cell activation. Since there is no need for human leukocyte antigen matching or prior exposure to the tumor antigens, NK-92 provides an opportunity for the development of next-generation off-the-shelf cell therapy platforms. CAR-engineered NK-92 cells have demonstrated robust antitumor activity in and preclinical studies, propelling the clinical development of CAR NK-92 cells. Preliminary phase 1 data indicate that CAR NK-92 can be safely administered in the clinic. In this review, we provide an overview of recent advances in the research and clinical application of this novel cell immunotherapy.

Citing Articles

Memory-like NK cell differentiation, inhibitory NKG2A blockade, and improved recognition via antibody or CAR engineering combine to enhance NK cell attack against multiple myeloma.

Zhou A, Marin N, Afrin S, Wong P, Tran J, Jacobs M J Immunol. 2025; 214(1):1-11.

PMID: 40073259 PMC: 11844139. DOI: 10.1093/jimmun/vkae004.

Differentiating Induced Pluripotent Stem Cells into Natural Killer Cells for Adoptive Cell Immunotherapies-Comparative Characterization of Current Protocols.

Budagova T, Efremova A, Usman N, Mokrousova D, Goldshtein D Int J Mol Sci. 2025; 26(3).

PMID: 39940874 PMC: 11816922. DOI: 10.3390/ijms26031107.

The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.

Yao P, Liu Y, Huang G, Hao L, Wang R Exp Hematol Oncol. 2024; 13(1):118.

PMID: 39633491 PMC: 11616395. DOI: 10.1186/s40164-024-00583-7.

Generation, Characterization, and Preclinical Studies of a Novel NKG2A-Targeted Antibody BRY805 for Cancer Immunotherapy.

Zhou Y, Wang Y, Liang J, Qian J, Wu Z, Gao Z Antibodies (Basel). 2024; 13(4).

PMID: 39584993 PMC: 11587108. DOI: 10.3390/antib13040093.

NK Cytotoxicity Mediated by NK-92 Cell Lines Expressing Combinations of Two Allelic Variants for .

Freitas Monteiro M, Papaserafeim M, Andreani M, Real A, Kouklas A, Reis Galvao D Antibodies (Basel). 2024; 13(3).

PMID: 39051331 PMC: 11270249. DOI: 10.3390/antib13030055.

References

Tartter P, Steinberg B, Barron D, Martinelli G . The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg. 1987; 122(11):1264-8. DOI: 10.1001/archsurg.1987.01400230050009. View

Schantz S, Savage H, Racz T, Taylor D, Sacks P . Natural killer cells and metastases from pharyngeal carcinoma. Am J Surg. 1989; 158(4):361-6. DOI: 10.1016/0002-9610(89)90134-7. View

Lanier L . Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008; 9(5):495-502. PMC: 2669298. DOI: 10.1038/ni1581. View

Guedan S, Calderon H, Posey Jr A, Maus M . Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019; 12:145-156. PMC: 6330382. DOI: 10.1016/j.omtm.2018.12.009. View

Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K . Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000; 356(9244):1795-9. DOI: 10.1016/S0140-6736(00)03231-1. View

Zhang W, Gordon M, Schultheis A, Yang D, Nagashima F, Azuma M . FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007; 25(24):3712-8. DOI: 10.1200/JCO.2006.08.8021. View

You F, Wang Y, Jiang L, Zhu X, Chen D, Yuan L . A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019; 9(1):64-78. PMC: 6356925. View

Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano M . NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Transl Med. 2019; 7(5):105. PMC: 6462666. DOI: 10.21037/atm.2019.01.42. View

Zhang G, Liu R, Zhu X, Wang L, Ma J, Han H . Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol Cell Biol. 2013; 91(10):615-24. DOI: 10.1038/icb.2013.45. View

10.

Meier R, Piert M, Piontek G, Rudelius M, Oostendorp R, Senekowitsch-Schmidtke R . Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. Nucl Med Biol. 2008; 35(5):579-88. DOI: 10.1016/j.nucmedbio.2008.02.006. View

11.

Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F . Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014; 8(2):297-310. PMC: 5528539. DOI: 10.1016/j.molonc.2013.12.001. View

12.

DAloia M, Zizzari I, Sacchetti B, Pierelli L, Alimandi M . CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018; 9(3):282. PMC: 5833816. DOI: 10.1038/s41419-018-0278-6. View

13.

Abel A, Yang C, Thakar M, Malarkannan S . Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9:1869. PMC: 6099181. DOI: 10.3389/fimmu.2018.01869. View

14.

Chen N, Li X, Chintala N, Tano Z, Adusumilli P . Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr Opin Immunol. 2018; 51:103-110. PMC: 5943172. DOI: 10.1016/j.coi.2018.03.002. View

15.

Muller T, Uherek C, Maki G, Chow K, Schimpf A, Klingemann H . Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2007; 57(3):411-23. PMC: 11029838. DOI: 10.1007/s00262-007-0383-3. View

16.

Swift B, Williams B, Kosaka Y, Wang X, Medin J, Viswanathan S . Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica. 2012; 97(7):1020-8. PMC: 3396673. DOI: 10.3324/haematol.2011.054254. View

17.

Boyiadzis M, Agha M, Redner R, Sehgal A, Im A, Hou J . Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017; 19(10):1225-1232. DOI: 10.1016/j.jcyt.2017.07.008. View

18.

Yu M, Luo H, Fan M, Wu X, Shi B, Di S . Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. Mol Ther. 2018; 26(2):366-378. PMC: 5835122. DOI: 10.1016/j.ymthe.2017.12.012. View

19.

Williams B, Law A, Routy B, denHollander N, Gupta V, Wang X . A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget. 2017; 8(51):89256-89268. PMC: 5687687. DOI: 10.18632/oncotarget.19204. View

20.

Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F . Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009; 27(7):1122-9. DOI: 10.1200/JCO.2008.18.0463. View